About NOXXON
NOXXON’s oncology-focused pipeline acts by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor micro-environment (TME), NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients with the latest update published in April 2020; further studies are being planned in these indications. In September 2019 NOXXON initiated an additional trial of NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset, NOX-E36 is a Phase 2 ready TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination.
|
Press ReleaseBerlin, Germany
2021, January 19 08:00 a.m. Half-yearly report on the liquidity contract with Invest Securities 2020, December 29 08:00 p.m. NOXXON announces initiation of NOX-A12 manufacturing for future clinical studies 2020, November 09 08:00 a.m. NOXXON announces that Data Safety Monitoring Board validates further NOX-A12 dose escalation in Phase 1/2 brain cancer study |
EventsESMO Immuno-Oncology
Aram Mangasarian, Jarl Ulf Jungnelius |